Switch to:
Also traded in: France, Germany, Italy, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.33
NYSE:SNY's Cash to Debt is ranked lower than
74% of the 723 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.47 vs. NYSE:SNY: 0.33 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:SNY' s Cash to Debt Range Over the Past 10 Years
Min: 0.14  Med: 9999.00 Max: N/A
Current: 0.33
Interest Coverage 10.26
NYSE:SNY's Interest Coverage is ranked lower than
74% of the 474 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 112.03 vs. NYSE:SNY: 10.26 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:SNY' s Interest Coverage Range Over the Past 10 Years
Min: 7.88  Med: 11.37 Max: 19.65
Current: 10.26
7.88
19.65
F-Score: 4
Z-Score: 1.82
M-Score: -2.00
WACC vs ROIC
8.47%
8.87%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 17.11
NYSE:SNY's Operating margin (%) is ranked higher than
80% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.51 vs. NYSE:SNY: 17.11 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:SNY' s Operating margin (%) Range Over the Past 10 Years
Min: 15.25  Med: 17.95 Max: 20.7
Current: 17.11
15.25
20.7
Net-margin (%) 11.54
NYSE:SNY's Net-margin (%) is ranked higher than
75% of the 684 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.44 vs. NYSE:SNY: 11.54 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:SNY' s Net-margin (%) Range Over the Past 10 Years
Min: 7.92  Med: 13.59 Max: 18.02
Current: 11.54
7.92
18.02
ROE (%) 9.10
NYSE:SNY's ROE (%) is ranked higher than
72% of the 711 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.23 vs. NYSE:SNY: 9.10 )
Ranked among companies with meaningful ROE (%) only.
NYSE:SNY' s ROE (%) Range Over the Past 10 Years
Min: 5.18  Med: 8.68 Max: 11.68
Current: 9.1
5.18
11.68
ROA (%) 5.23
NYSE:SNY's ROA (%) is ranked higher than
72% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.70 vs. NYSE:SNY: 5.23 )
Ranked among companies with meaningful ROA (%) only.
NYSE:SNY' s ROA (%) Range Over the Past 10 Years
Min: 2.62  Med: 5.11 Max: 7.03
Current: 5.23
2.62
7.03
ROC (Joel Greenblatt) (%) 48.63
NYSE:SNY's ROC (Joel Greenblatt) (%) is ranked higher than
89% of the 729 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.81 vs. NYSE:SNY: 48.63 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:SNY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 31.75  Med: 43.08 Max: 63.82
Current: 48.63
31.75
63.82
Revenue Growth (3Y)(%) -1.00
NYSE:SNY's Revenue Growth (3Y)(%) is ranked lower than
72% of the 581 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. NYSE:SNY: -1.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:SNY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -1.5  Med: 6.50 Max: 27.4
Current: -1
-1.5
27.4
EBITDA Growth (3Y)(%) -4.40
NYSE:SNY's EBITDA Growth (3Y)(%) is ranked lower than
65% of the 528 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.30 vs. NYSE:SNY: -4.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:SNY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -5.2  Med: 5.70 Max: 35.7
Current: -4.4
-5.2
35.7
EPS Growth (3Y)(%) -8.10
NYSE:SNY's EPS Growth (3Y)(%) is ranked lower than
68% of the 483 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.60 vs. NYSE:SNY: -8.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:SNY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -12.8  Med: 3.40 Max: 41.4
Current: -8.1
-12.8
41.4
» NYSE:SNY's 10-Y Financials

Financials (Next Earnings Date: 2016-02-09)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

SNY Guru Trades in Q1 2015

Paul Tudor Jones 7,598 sh (New)
NWQ Managers 3,927,517 sh (+33.50%)
John Buckingham 24,608 sh (+9.89%)
HOTCHKIS & WILEY 11,782,180 sh (+0.77%)
Charles Brandes 2,573,969 sh (+0.08%)
Bill Nygren 5,670,000 sh (unchged)
Francis Chou 410,000 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
David Dreman 1,102 sh (unchged)
Third Avenue Management Sold Out
First Eagle Investment Sold Out
Steven Cohen Sold Out
Ken Fisher 13,058,095 sh (-0.21%)
Murray Stahl 26,185 sh (-0.42%)
Scott Black 175,625 sh (-0.47%)
Dodge & Cox 43,034,073 sh (-0.55%)
James Barrow 30,225,221 sh (-1.88%)
Sarah Ketterer 477,367 sh (-5.81%)
PRIMECAP Management 3,972,907 sh (-7.33%)
Mario Gabelli 4,700 sh (-9.53%)
Manning & Napier Advisors, Inc 2,499,440 sh (-54.00%)
» More
Q2 2015

SNY Guru Trades in Q2 2015

Lee Ainslie 101,650 sh (New)
John Buckingham 132,190 sh (+437.18%)
Dodge & Cox 49,765,693 sh (+15.64%)
Manning & Napier Advisors, Inc 2,879,307 sh (+15.20%)
Sarah Ketterer 516,115 sh (+8.12%)
Scott Black 178,437 sh (+1.60%)
Ken Fisher 13,246,593 sh (+1.44%)
Mario Gabelli 4,700 sh (unchged)
Francis Chou 410,000 sh (unchged)
David Dreman 1,102 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
Bill Nygren 5,670,000 sh (unchged)
Paul Tudor Jones Sold Out
Charles Brandes 2,560,460 sh (-0.52%)
Murray Stahl 26,000 sh (-0.71%)
James Barrow 29,961,207 sh (-0.87%)
PRIMECAP Management 3,756,457 sh (-5.45%)
HOTCHKIS & WILEY 10,701,542 sh (-9.17%)
NWQ Managers 2,636,361 sh (-32.87%)
» More
Q3 2015

SNY Guru Trades in Q3 2015

Paul Tudor Jones 5,809 sh (New)
Sarah Ketterer 574,783 sh (+11.37%)
Murray Stahl 27,000 sh (+3.85%)
John Buckingham 133,116 sh (+0.70%)
Ken Fisher 13,295,966 sh (+0.37%)
Dodge & Cox 49,859,813 sh (+0.19%)
Mario Gabelli 4,700 sh (unchged)
David Dreman 1,102 sh (unchged)
Manning & Napier Advisors, Inc 2,879,307 sh (unchged)
Lee Ainslie 101,650 sh (unchged)
Bill Nygren 5,670,000 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
Francis Chou 410,000 sh (unchged)
Manning & Napier Advisors, Inc 2,819,031 sh (-2.09%)
Scott Black 173,432 sh (-2.80%)
James Barrow 29,123,564 sh (-2.80%)
NWQ Managers 2,501,826 sh (-5.10%)
Charles Brandes 2,290,031 sh (-10.56%)
HOTCHKIS & WILEY 9,035,695 sh (-15.57%)
PRIMECAP Management 2,939,082 sh (-21.76%)
» More
Q4 2015

SNY Guru Trades in Q4 2015

James Barrow 29,489,368 sh (+1.26%)
Ken Fisher 13,416,220 sh (+0.90%)
Mario Gabelli 4,700 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:SNY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Sanofi SA

Bill Nygren Comments on Sanofi - Apr 08, 2014

Sanofi (SNY - $52)(SNY)
Sanofi is a pharmaceutical company with a good mix of durable businesses with strong growth characteristics. The company has a strong franchise in diabetes treatments, maintaining dominant market share in this rapidly growing category. Sanofi is a leading player in emerging markets, where sales growth rates are twice that of the overall pharmaceutical market. Sanofi is also a leader in vaccines, and they have a strong footprint in over-the-counter products. We think that margins and profitability should improve as the company leverages fixed R&D spending and enforces good cost controls. The company’s balance sheet has more cash than debt, and the shares sell at a substantial discount to our estimate of intrinsic value. Moreover, Sanofi has a dividend yield of 3.7%.

From Bill Nygren (Trades, Portfolio)'s Oakmark Fund first quarter 2014 commentary.

Check out Bill Nygren latest stock trades

Top Ranked Articles about Sanofi SA

Weekly 3-Year Low Highlights: Sanofi, Exelon, Cummins, W.W. Grainger A look at companies whose stocks have recently reached their 3-year lows
According to GuruFocus list of 3-year lows, Sanofi (NYSE:SNY), Exelon Corp. (NYSE:EXC), Cummins Inc. (NYSE:CMI) and W.W. Grainger Inc. (NYSE:GWW) have all reached their three-year lows. Read more...
John Buckingham Buys 10 New Stakes in Second Quarter
John Buckingham (Trades, Portfolio), chief investment officer of AFAM (Al Frank Asset Management) Capital, which specializes in managing exchange-traded funds and equity portfolios, and editor of The Prudent Investor, an investment newsletter, learned the ropes from value investor Al Frank. The Al Frank Fund posted returns of 5.47% in 2014, 37.06% in 2013 and 17.26% in 2012. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 19.70
SNY's P/E(ttm) is ranked higher than
71% of the 795 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.86 vs. SNY: 19.70 )
Ranked among companies with meaningful P/E(ttm) only.
SNY' s P/E(ttm) Range Over the Past 10 Years
Min: 9.64  Med: 20.57 Max: 38.97
Current: 19.7
9.64
38.97
Forward P/E 12.24
SNY's Forward P/E is ranked higher than
75% of the 419 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.50 vs. SNY: 12.24 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 19.80
SNY's PE(NRI) is ranked higher than
70% of the 555 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.45 vs. SNY: 19.80 )
Ranked among companies with meaningful PE(NRI) only.
SNY' s PE(NRI) Range Over the Past 10 Years
Min: 9.82  Med: 20.57 Max: 39.2
Current: 19.8
9.82
39.2
P/B 1.66
SNY's P/B is ranked higher than
71% of the 928 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.54 vs. SNY: 1.66 )
Ranked among companies with meaningful P/B only.
SNY' s P/B Range Over the Past 10 Years
Min: 1.11  Med: 1.73 Max: 2.38
Current: 1.66
1.11
2.38
P/S 5.30
SNY's P/S is ranked higher than
52% of the 929 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.60 vs. SNY: 5.30 )
Ranked among companies with meaningful P/S only.
SNY' s P/S Range Over the Past 10 Years
Min: 2.37  Med: 3.98 Max: 7.32
Current: 5.3
2.37
7.32
PFCF 38.76
SNY's PFCF is ranked lower than
57% of the 485 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 31.85 vs. SNY: 38.76 )
Ranked among companies with meaningful PFCF only.
SNY' s PFCF Range Over the Past 10 Years
Min: 15.02  Med: 33.11 Max: 82.54
Current: 38.76
15.02
82.54
POCF 28.12
SNY's POCF is ranked lower than
59% of the 651 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 22.68 vs. SNY: 28.12 )
Ranked among companies with meaningful POCF only.
SNY' s POCF Range Over the Past 10 Years
Min: 12.19  Med: 27.46 Max: 64.69
Current: 28.12
12.19
64.69
EV-to-EBIT 32.11
SNY's EV-to-EBIT is ranked lower than
75% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.42 vs. SNY: 32.11 )
Ranked among companies with meaningful EV-to-EBIT only.
SNY' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.3  Med: 20.60 Max: 200.9
Current: 32.11
8.3
200.9
EV-to-EBITDA 23.54
SNY's EV-to-EBITDA is ranked lower than
69% of the 852 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.91 vs. SNY: 23.54 )
Ranked among companies with meaningful EV-to-EBITDA only.
SNY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.5  Med: 13.60 Max: 129.7
Current: 23.54
6.5
129.7
Shiller P/E 20.07
SNY's Shiller P/E is ranked higher than
81% of the 166 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 43.90 vs. SNY: 20.07 )
Ranked among companies with meaningful Shiller P/E only.
SNY' s Shiller P/E Range Over the Past 10 Years
Min: 13.58  Med: 21.37 Max: 28.3
Current: 20.07
13.58
28.3
Current Ratio 1.35
SNY's Current Ratio is ranked lower than
74% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.28 vs. SNY: 1.35 )
Ranked among companies with meaningful Current Ratio only.
SNY' s Current Ratio Range Over the Past 10 Years
Min: 0.79  Med: 1.53 Max: 2.71
Current: 1.35
0.79
2.71
Quick Ratio 0.91
SNY's Quick Ratio is ranked lower than
77% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.68 vs. SNY: 0.91 )
Ranked among companies with meaningful Quick Ratio only.
SNY' s Quick Ratio Range Over the Past 10 Years
Min: 0.46  Med: 1.02 Max: 2.41
Current: 0.91
0.46
2.41
Days Inventory 181.16
SNY's Days Inventory is ranked lower than
56% of the 639 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 119.42 vs. SNY: 181.16 )
Ranked among companies with meaningful Days Inventory only.
SNY' s Days Inventory Range Over the Past 10 Years
Min: 155.87  Med: 184.87 Max: 378.1
Current: 181.16
155.87
378.1
Days Sales Outstanding 109.41
SNY's Days Sales Outstanding is ranked lower than
53% of the 584 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.67 vs. SNY: 109.41 )
Ranked among companies with meaningful Days Sales Outstanding only.
SNY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.29  Med: 70.59 Max: 83.73
Current: 109.41
61.29
83.73
Days Payable 175.43
SNY's Days Payable is ranked higher than
74% of the 563 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.59 vs. SNY: 175.43 )
Ranked among companies with meaningful Days Payable only.
SNY' s Days Payable Range Over the Past 10 Years
Min: 99.73  Med: 127.73 Max: 327.18
Current: 175.43
99.73
327.18

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 4.04
SNY's Dividend Yield is ranked higher than
87% of the 678 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.43 vs. SNY: 4.04 )
Ranked among companies with meaningful Dividend Yield only.
SNY' s Dividend Yield Range Over the Past 10 Years
Min: 1.41  Med: 3.68 Max: 5.46
Current: 4.04
1.41
5.46
Dividend Payout 0.79
SNY's Dividend Payout is ranked lower than
87% of the 418 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. SNY: 0.79 )
Ranked among companies with meaningful Dividend Payout only.
SNY' s Dividend Payout Range Over the Past 10 Years
Min: 0.39  Med: 2.37 Max: 8.15
Current: 0.79
0.39
8.15
Dividend Growth (3y) 3.80
SNY's Dividend Growth (3y) is ranked lower than
57% of the 279 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.30 vs. SNY: 3.80 )
Ranked among companies with meaningful Dividend Growth (3y) only.
SNY' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 6.50 Max: 29.6
Current: 3.8
0
29.6
Forward Dividend Yield 4.04
SNY's Forward Dividend Yield is ranked higher than
86% of the 614 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.56 vs. SNY: 4.04 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 5.18
SNY's Yield on cost (5-Year) is ranked higher than
85% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.79 vs. SNY: 5.18 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
SNY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 1.8  Med: 4.70 Max: 6.97
Current: 5.18
1.8
6.97
3-Year Average Share Buyback Ratio -0.10
SNY's 3-Year Average Share Buyback Ratio is ranked higher than
79% of the 458 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -2.90 vs. SNY: -0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SNY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -24.6  Med: -0.30 Max: 1.3
Current: -0.1
-24.6
1.3

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 60.25
SNY's Price/Tangible Book is ranked lower than
99% of the 889 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.76 vs. SNY: 60.25 )
Ranked among companies with meaningful Price/Tangible Book only.
SNY' s Price/Tangible Book Range Over the Past 10 Years
Min: 6.48  Med: 13.35 Max: 2093.5
Current: 60.25
6.48
2093.5
Price/Projected FCF 1.38
SNY's Price/Projected FCF is ranked higher than
78% of the 523 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.32 vs. SNY: 1.38 )
Ranked among companies with meaningful Price/Projected FCF only.
SNY' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.9  Med: 1.71 Max: 24.12
Current: 1.38
0.9
24.12
Price/Median PS Value 1.33
SNY's Price/Median PS Value is ranked higher than
69% of the 899 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.15 vs. SNY: 1.33 )
Ranked among companies with meaningful Price/Median PS Value only.
SNY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.63  Med: 1.00 Max: 6.17
Current: 1.33
0.63
6.17
Price/Graham Number 7.27
SNY's Price/Graham Number is ranked lower than
93% of the 641 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.21 vs. SNY: 7.27 )
Ranked among companies with meaningful Price/Graham Number only.
SNY' s Price/Graham Number Range Over the Past 10 Years
Min: 1.92  Med: 3.29 Max: 41.05
Current: 7.27
1.92
41.05
Earnings Yield (Greenblatt) (%) 3.10
SNY's Earnings Yield (Greenblatt) (%) is ranked higher than
74% of the 720 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. SNY: 3.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SNY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.5  Med: 4.90 Max: 12
Current: 3.1
0.5
12
Forward Rate of Return (Yacktman) (%) 6.28
SNY's Forward Rate of Return (Yacktman) (%) is ranked lower than
66% of the 318 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.62 vs. SNY: 6.28 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
SNY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 5.4  Med: 18.60 Max: 44.3
Current: 6.28
5.4
44.3

More Statistics

Revenue(Mil) $36771
EPS $ 1.98
Beta0.99
Short Percentage of Float0.09%
52-Week Range $38.58 - 54.98
Shares Outstanding(Mil)2622.05

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 40,632 40,855 42,139 41,658
EPS($) 3.05 3.11 3.19 2.83
EPS without NRI($) 3.05 3.11 3.19 2.83

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:SAN.France, SNW.Germany, SANF.Italy, SNYN.Mexico, SAN.Switzerland, 0O59.UK, SNYNF.USA,
Sanofi SA was incorporated under the laws of France on April 28,1994 as a société anonyme, a form of limited liability company. It is a healthcare company, engaged in the research, development, manufacture and marketing of healthcare products. Its principal activities include Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. It also operates through the following platforms: Emerging Markets, Diabetes Solutions, Vaccines, Consumer Health Care (CHC), Animal Health, Genzyme, and Other Innovative Products. The Pharmaceuticals segment covers research, development, production and marketing of medicines, including activities acquired with Genzyme. Sanofi's pharmaceuticals portfolio consists of flagship products, plus prescription medicines, generic medicines, and consumer health products. This segment also includes all associates and joint ventures whose activities are related to pharmaceuticals, in particular the entities majority owned by BMS. The Vaccines segment is wholly dedicated to vaccines, including research, development, production and marketing. This segment includes Sanofi Pasteur MSD joint venture with Merck & Co., Inc. in Europe. The Animal Health segment comprises the research, development, production and marketing activities of Merial, which offers medicines and vaccines for a wide variety of animal species. Its competitors include Novo Nordisk, Merck, Eli Lilly, Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Shire, Pfizer, Biogen Idec, Teva and Merck Serono, Bayer, Roche, Johnson & Johnson, AstraZeneca, Boehringer-Ingelheim, Fresenius Medical Care, among others. The Company's products and manufacturing facilities are subject to significant government regulations and approvals.
» More Articles for SNY

Headlines

Articles On GuruFocus.com
Dodge & Cox Global Stock Fund 4th Quarter Commentary Jan 19 2016 
Dodge & Cox Stock Fund 2015 Commentary Jan 18 2016 
Why MannKind Could Be a Value Trap Jan 04 2016 
Francis Chou's Holdings Trading at Low PE Dec 23 2015 
Warren Buffett Further Pares Munich Re Stake Dec 14 2015 
Weekly 3-Year Low Highlights: Sanofi, Exelon, Cummins, W.W. Grainger Nov 18 2015 
Why Warren Buffett Sold Munich Re Oct 06 2015 
MS Global Franchise Fund Reduces Positions in Sanofi, Diageo Sep 16 2015 
Third Avenue International Value Fund Part 2 Sep 10 2015 
Dodge & Cox Funds' 2015 Equity Mid-Year Review Aug 19 2015 

More From Other Websites
Trade Boost From Trans-Pacific Partnership? Feb 06 2016
Drug Manufacturers - Major Equities Technical Updates -- TherapeuticsMD, Sanofi, Shire, and Novartis Feb 04 2016
Sanofi Begins Search for Vaccine for Zika Virus as Fear Grows Feb 03 2016
First U.S. Zika virus transmission reported, attributed to sex Feb 03 2016
First U.S. Zika virus transmission reported, attributed to sex Feb 03 2016
Moderate Improvements in Blood Glucose Levels Could Deliver Significant Benefits for People With... Feb 03 2016
[$$] Drug Industry Starts Race to Develop Zika Vaccine Feb 03 2016
The Latest: Chile reports its first 3 confirmed Zika cases Feb 02 2016
The Latest: Chile reports its first 3 confirmed Zika cases Feb 02 2016
First U.S. Zika virus transmission reported, sexual transmission cited Feb 02 2016
Cambridge developer of cystic fibrosis drugs joins choppy IPO waters Feb 02 2016
Quest for Zika vaccine widens; Africa, Asia deemed vulnerable Feb 02 2016
Video-Q3 2015 RESULTS for Sanofi Feb 02 2016
Merck, Sanofi Exploring Potential End To Joint Venture In Europe Feb 02 2016
[$$] Sanofi to Launch Zika Vaccine Research Feb 02 2016
Sanofi plans 600 job cuts in France over 3 years Feb 02 2016
Drugmaker Sanofi Pasteur launches effort for Zika vaccine Feb 02 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK